# Alex Lugovskoy

> Alex Lugovskoy is the co-founder and CEO of Diagonal Therapeutics, an Atlas Venture advisor, and a director and scientific advisor at Valink Therapeutics. Trained in mathematics, physics and biophysics, he held leadership roles at Biogen, Merrimack, Morphic and Dragonfly before co-founding Diagonal with Atlas in 2022. His professional record includes more than 100 patents and manuscripts, journal editing, and participation in the antibody-engineering community.

- **Role:** Co-Founder & Chief Executive Officer at Diagonal Therapeutics
- **Organizations:** Diagonal Therapeutics, Atlas Venture, Valink Therapeutics, Dragonfly Therapeutics, Morphic Therapeutic, Merrimack Pharmaceuticals, Biogen, mAbs, The Antibody Society
- **Education:** B.Sc. in Mathematics and Physics, Moscow Institute of Physics and Technology, M.Sc. in Molecular Biophysics, Moscow Institute of Physics and Technology, Ph.D. in Biophysics, Harvard University, Advanced Certificate for Executives in Management, Innovation and Technology, MIT Sloan School of Management
- **Known for:** Co-founded Diagonal Therapeutics with Atlas Venture in 2022., Led Diagonal at its $128 million public financing launch in 2024 and $125 million Series B announcement in 2026., Author or co-author of over 100 patents and manuscripts, according to Atlas Venture.

## Career timeline

- **2001-2010** — Worked at Biogen, serving as Associate Director of Drug Discovery.
- **2010-2016** — Worked at Merrimack Pharmaceuticals, serving as Vice President of Therapeutics.
- **2016-2020** — Chief Development Officer at Morphic Therapeutic.
- **2020** — Dragonfly announced his appointment as Chief Operating Officer on November 24.
- **2022** — Co-founded Diagonal Therapeutics with Atlas Venture.
- **2023** — Joined Valink Therapeutics’ board of directors.
- **2024** — Diagonal launched publicly with $128 million in financing on April 3. Valink named him to its scientific advisory board in December.
- **2026** — Diagonal announced a $125 million Series B in January and appointed Jonathan Piazza as CFO in May.

## Achievements

- Co-founded Diagonal Therapeutics with Atlas Venture in 2022.
- Led Diagonal at its $128 million public financing launch in 2024 and $125 million Series B announcement in 2026.
- Author or co-author of over 100 patents and manuscripts, according to Atlas Venture.
- Built and led multiple operating and development functions at Morphic.
- Former board director of The Antibody Society.
- Director and scientific advisor at Valink Therapeutics.

## Latest updates

- **2026-05** — Diagonal appointed Jonathan Piazza as CFO; Lugovskoy highlighted his capital formation and company-building experience.
- **2026-01** — Diagonal announced an oversubscribed $125 million Series B co-led by Sanofi Ventures and Janus Henderson Investors.

## Links

- Website: https://diagonaltx.com/
- LinkedIn: https://www.linkedin.com/in/alexlugovskoy

---

Profile page: https://yespress.io/alex-lugovskoy
Published by YesPress — https://yespress.io
Last updated: 2026-10-16